Select a year
allDate
Subject
File download
2025.11.19
Announcement: The company's directors and others have reached a settlement agreement with the Securities and Futures Investors Protection Center in a civil lawsuit
2025.11.05
Announcement of changes in the company's chief financial officer, chief accounting officer, and acting spokesperson
2025.08.26
Announcement: Our company has received a ruling from the National Taxation Bureau regarding a correction of its business tax
2025.08.20
Announcement: Our company has received the National Taxation Bureau's Notice of Correction for Corporate Income Tax Settlement Declaration, Payment Receipt, and Ruling, among other documents, for the fiscal years 2020 to 2021
2025.08.07
The company's board of directors has resolved to acquire 100% equity interest in Amenie Technology Co., Ltd., Thailand
2025.08.07
Announcement: The Board of Directors of the Company has approved the financial report for the second quarter of 2025
2025.07.18
Announcement: Our company has received the National Taxation Bureau's Notice of Correction for Corporate Income Tax Settlement Declarations, Payment Receipts, and Rulings for the fiscal years 2017 to 2019
2025.05.27
Announcement regarding matters related to the ex-dividend date (cash dividend of NTD 1.5 per share)
2025.05.27
Announcement of Important Resolutions of the Company's 2025 Annual General Meeting of Shareholders
2025.05.06
Announcement: The Company has received a complaint from the Intellectual Property and Commercial Court
2025.04.11
The company's board of directors has resolved to distribute dividends (a cash dividend of NTD 1.5 per share)
2025.04.11
Announcement: The Board of Directors of the Company has approved the 2024 Financial Report
2025.04.11
The Board of Directors of the Company has approved the 2024 Annual Employee Remuneration and Directors Remuneration
2025.04.11
Announcement: The company's board of directors has resolved to convene the 2025 Annual General Meeting of Shareholders (location changed)
2025.04.11
The Board of Directors of the Company hereby announces the approval of the appointment of the Chief Financial Officer, Chief Accountant, and Acting Spokesperson.
2025.03.31
Announcement of changes in the company's chief financial officer, chief accounting officer, and acting spokesperson.
2025.03.07
Announcement of the Company's Board of Directors' resolution to convene the 2025 Annual General Meeting of Shareholders
2025.03.07
Announcement of the resignation of the company's chief financial officer, chief accounting officer, and acting spokesperson
2025.02.21
Announcement: Our company's generic drug product, Ansumma Injection (100 mg/mL), has received approval from the Ministry of Health and Welfare
2024.12.27
The Company's Board of Directors has resolved to establish a Sustainable Development Committee and appoint the first members of the Sustainable Development Committee
2024.08.08
Key operational executives of the company have been reassigned. (Supplementary date of board approval)
2024.08.08
The Board of Directors of the Company hereby announces that it has approved the financial report for the second quarter of 2024
2024.07.04
Announcement of the newly appointed members of the Company's Compensation and Remuneration Committee
2024.06.13
Announcement of the resignation of a member of the Company's Compensation and Remuneration Committee
2024.05.27
Announcement of the list of directors (including independent directors) elected at the 2024 Annual General Meeting of Shareholders
2024.05.27
Announcement of the resolution passed at the 2024 Annual General Meeting of Shareholders to lift the non-compete restrictions on newly appointed directors and their representatives
2024.05.27
Announcement regarding matters related to the ex-dividend date (cash dividend of NTD 2.5 per share)
2024.05.27
Announcement of Important Resolutions of the Company's 2024 Annual General Meeting of Shareholders
2024.05.23
Supplement to the announcement dated May 17, 2024: The company's board of directors resolved to authorize the chairman to purchase real estate
2024.05.17
The Board of Directors of this Company has resolved to authorize the Chairman to purchase real estate
2024.03.25
The Board of Directors of the Company has approved the 2023 Employee Remuneration and Director Remuneration
2024.03.25
The Board of Directors of the Company hereby announces that it has approved the 2012 Annual Financial Report
2024.01.30
Announcement of the Company's Board of Directors' resolution to convene the 2024 Annual General Meeting of Shareholders
2023.12.06
Announcement: Our company has been fined NT$200,000 for violating the Medical Devices Administration Act
2023.11.20
Announcement: The company's board of directors has approved the change of general manager
2023.09.26
Our company's long-acting pain reliever injection, Naldebain, has obtained import drug approval from Brunei
2023.08.08
The Board of Directors of the Company hereby announces that it has approved the financial report for the second quarter of 2023
2023.07.21
Cooperating with the Taipei City Investigation Office of the Investigation Bureau, Ministry of Justice, in the investigation
2023.04.17
The Board of Directors of the Company hereby announces that it has approved the 2022 Annual Financial Report
2023.04.17
Announcement of the Company's Board of Directors' Resolution to Transfer Surplus to Capital Increase and Issue New Shares
2023.04.17
Announcement Regarding the Board of Directors' Resolution to Convene the 2023 Annual General Meeting of Shareholders (with Additional Reasons for Convening)
2023.03.13
Announcement of the Company's Board of Directors' resolution to convene the 2023 Annual General Meeting of Shareholders
2022.08.23
Our HeraDerm Scar care Dressing (non-sterile) has obtained import medical device approval from the Philippine Food and Drug Administration
2022.08.15
Correction to the Company’s Second Quarter Individual Financial Report and iXBRL Information
2022.08.08
Announcement of the Board of Directors' resolution regarding matters related to the ex-rights date in 2022
2022.08.08
The Board of Directors of the Company hereby announces that it has approved the financial report for the first half of 2022
2022.06.22
Announcement: Our company has been invited to participate in the online investor briefing for emerging stock market companies hosted by First Securities.
2022.06.05
Our company's long-acting analgesic injection, Naldebain, has obtained import drug approval in Malaysia.
2022.04.12
Supplementary Announcement Regarding the Board of Directors' Resolution to Convene the 2022 Annual General Meeting of Shareholders
2022.04.12
Announcement of the Company's Board of Directors' Resolution to Transfer Surplus to Capital Increase and Issue New Shares
2022.03.02
Announcement: The company's board of directors has approved the change of general manager
2022.03.02
The Board of Directors of the Company has approved the proposal for the Chairman to concurrently serve as CEO
2022.03.02
The company's board of directors has approved the promotion of key operational executives
2022.03.02
Announcement: The company's board of directors has approved the ratification of the appointment of the head of research and development
2022.03.02
Announcement of the Board of Directors' resolution to convene the 2022 Annual General Meeting of Shareholders
2021.12.29
Our company's long-acting analgesic injection, Naldebain, has obtained import drug approval in Thailand
2021.08.12
Announcement of the Board of Directors' resolution regarding matters related to the ex-rights date in 2021
2021.08.12
Announcement of the Board of Directors' resolution to apply for listing of the company's shares on the Emerging Stock Market
2021.08.12
The company's board of directors has resolved to establish a remuneration committee and appoint the first remuneration committee members
2021.07.28
Correction to the information disclosed in the notes to the Company’s 2020 Individual Financial Report
2021.07.15
Announcement of the resolution passed at the Company's 2021 Annual General Meeting to lift the non-compete restrictions on newly appointed directors
2021.07.15
Announcement of the list of directors (including independent directors) elected at the 2021 Annual General Meeting of Shareholders, marking one-third of the board of directors being replaced
2021.06.25
Announcement: The company's board of directors has resolved to change the date of the 2021 Annual General Meeting of Shareholders (in accordance with the Financial Supervisory Commission's announcement "Measures for Postponing Shareholders' Meetings of Publicly Listed Companies in Response to the Epidemic")
2021.05.21
The Company has suspended the scheduled shareholders' meeting in accordance with the instructions of the Financial Supervisory Commission
2021.03.09
Announcement of the Company's Board of Directors' Resolution to Transfer Surplus to Capital Increase and Issue New Shares
2021.03.09
Announcement of the Company's Board of Directors' resolution to convene the 2021 Annual General Meeting of Shareholders
2020.12.16
Our company's long-acting analgesic injection, Naldebain, has obtained import drug approval from the Singapore HSA